|
|
 |
|
Viewing report
|
|
|
|
Japanese Pharma to 2008: Innovation and Expansion Will Counter the Western Threat
Datamonitor, Jan 2003, Pages: 383
Table of Contents
Chapter 1 Executive Summary 3
Scope 3
Datamonitor’s insight into the Japanese Pharmaceutical market in 2003 3
Japanese companies must focus on R&D due to the weaknesses of their mature portfolios. 4
In order to expand internationally the ultimate aim is to establish strong independent overseas operations, but to achieve this the companies must choose the most appropriate route for their size 6
Overseas companies must consider their therapeutic focus and existing marketing capabilities to determine the most successful Japanese expansion strategy 8
Fujisawa is forecast to be the best performing Japanese company to 2008, because it is reaping the rewards of its extensive alliance network, which includes 20 new corporate agreements from January 2000 to October 2003. 9
Chapter 2 KEY EVENTS IMPACTING THE JAPANESE PHARMACEUTICAL MARKET, 2002-03 30
Key findings 30
Introduction 31
Changes to the co-payment system 32
Implications 32
NHI pricing system 33
Impact of NHI price revisions in 2002 33
Generic drugs 33
The future 34
Biotechnology 36
Chapter 3 WINNERS AND LOSERS; BENCHMARKING JAPANESE COMPANY PERFORMANCE TO 2008 37
Key findings 37
Company benchmarking 38
The competitive position of the Japanese pharmaceutical companies reveals the winners and losers in 2002 38
Analysis of the ethical sales forecasts to 2008 shows the companies with the strongest growth potential 40
Regional sales analysis reveals the most international companies in 2002 were Eisai, Fujisawa and Takeda 41
Portfolio maturity analyis reveals the companies that need to take strategic action to safeguard future growth 43
Reliance on in-licensed drugs varies greatly across the companies 46
Focus on R&D increases 47
The Japanese pharmaceutical companies relance on higher value products will rise over the next six years 51
Sales force benchmarking reveals that there is only a limited variation between the large and small domestic companies 53
Alliance analysis reveals the differences between the companies business models 54
Financial benchmarking 63
Profitability measures 63
Liquidity and solvency measures 69
Chapter 4 STRATEGIC IMPLICATIONS FOR JAPANESE PHARMACEUTICAL COMPANIES 73
Key findings 73
Product-sourcing strategies 75
Opportunities for in-licensing from western companies are declining 75
Licensing: A useful source of products to boost portfolios in the short-term, but not a long-term strategy for growth 76
International Conference on Harmonization aids western company penetration 78
The backlog of mature western drugs awaiting Japanese approval will intensify competition for Japanese companies 78
In-licensing opportunities still exist for mature and competitive Japanese markets 79
R&D: Essential for long-term potential 80
Domestic expansion/survival strategies 83
Consolidation may become a neccessity rather than an option 84
Geographical expansion strategies 86
Out-Licensing: A solid first step 88
Joint ventures: A winning formula? 89
Alliance networks drive stronger sales while allowing the Japanese company to retain control 90
M&A 92
Stand-alone overseas operations; the ultimate aim 92
Chapter 5 IMPLICATIONS FOR WESTERN PHARMA COMPANIES SEEKING EXPANSION OPPORTUNITIES IN JAPAN 93
Key findings 93
Recent changes in the position of western pharmaceutical companies in Japan highlight the importance of this market 94
What are the main motivations for the increased interest of western companies in the Japanese pharmaceutical market? 94
Expanding the potential market size 94
Lifecycle management 98
Evaluation of expansion strategies 98
Achieving expansion through corporate agreements and alliance networks 99
Joint Ventures: A key route to better industry knowledge 101
Acquisitions accelerate expansion 102
Independent operation: The goal 103
Chapter 6 JAPANESE PHARMACEUTICAL COMPANY PROFILES 104
Chugai 104
Strategy 105
Portfolio and pipeline analysis 110
R&D 115
Daiichi 120
Strategy 121
Portfolio and pipeline analysis 125
R&D 128
Dainippon 132
Strategy 133
Portfolio and pipeline analysis 137
R&D 144
Eisai 150
Strategy 151
Portfolio and pipeline analysis 157
R&D 163
Fujisawa 169
Strategy 170
Portfolio and pipeline analysis 174
R&D 179
Japan Tobacco 183
Strategy 183
Portfolio and pipeline analysis 188
R&D 192
Kirin Brewery 197
Strategy 198
Portfolio and pipeline analysis 204
R&D 207
Kyorin 210
Strategy 211
Portfolio and pipeline analysis 217
R&D 223
Kyowa Hakko Kogyo 227
Strategy 227
Portfolio and pipeline analysis 233
R&D 238
Mitsubishi Pharma 241
Strategy 242
Portfolio and pipeline analysis 246
R&D 251
Ono Pharmaceuticals 254
Strategy 254
Portfolio and pipeline analysis 259
R&D 266
Sankyo 271
Strategy 273
Portfolio and pipeline analysis 279
R&D 285
Shionogi 289
Strategy 290
Portfolio and pipeline analysis 296
R&D 301
Sumitomo Pharmaceuticals 309
Strategy 310
Portfolio and pipeline analysis 314
R&D 319
Takeda 322
Strategy 323
Portfolio and pipeline analysis 330
R&D 338
Tanabe 342
Strategy 343
Portfolio and pipeline analysis 349
R&D 354
Yamanouchi 357
Strategy 358
Portfolio and pipeline analysis 364
R&D 370
Chapter 7 APPENDIX 377
Japanese Pharmaceutical Market Background 377
Lack of western penetration 377
Report methodology 380
Exchange rates 380
About Datamonitor 381
About Datamonitor Healthcare 381
Datamonitor Healthcare’s research and analysis methodologies 382
Datamonitor Healthcare’s therapy area capabilities 382
Datamonitor’s Competitive Intelligence Business Unit 383
Customers who bought this item also bought
Br. Holdings Corporation
Br Malls Participacoes Sa
The 2009 Import and Export Market for Butadiene Rubber (BR) in Japan
The World Market for Butadiene Rubber (BR): A 2009 Global Trade Perspective
The 2009 Import and Export Market for Butadiene Rubber (BR) in Slovakia
The 2009 Import and Export Market for Butadiene Rubber (BR) in Iran
The 2009 Import and Export Market for Butadiene Rubber (BR) in Belarus
The 2009 Import and Export Market for Butadiene Rubber (BR) in Bulgaria
The 2009 Import and Export Market for Butadiene Rubber (BR) in Colombia
The 2009 Import and Export Market for Butadiene Rubber (BR) in Estonia
The 2009 Import and Export Market for Butadiene Rubber (BR) in Turkey
The 2009 Import and Export Market for Butadiene Rubber (BR) in Uruguay
|
|
|
|
